Jeff Johnson
Stock Analyst at Baird
(4.71)
# 156
Out of 4,876 analysts
141
Total ratings
61.22%
Success rate
30.26%
Average return
Main Sectors:
Stocks Rated by Jeff Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COO The Cooper Companies | Maintains: Outperform | $107 → $97 | $69.69 | +39.19% | 17 | May 30, 2025 | |
| NVST Envista Holdings | Upgrades: Outperform | $21 → $23 | $19.65 | +17.05% | 8 | May 27, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $130 → $115 | $91.74 | +25.35% | 14 | May 6, 2025 | |
| DXCM DexCom | Maintains: Outperform | $115 → $105 | $85.04 | +23.47% | 14 | May 2, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $33 → $24 | $19.11 | +25.59% | 16 | May 1, 2025 | |
| ALC Alcon | Maintains: Outperform | $104 → $108 | $87.17 | +23.90% | 9 | Feb 27, 2025 | |
| BBNX Beta Bionics | Initiates: Neutral | $20 | $14.99 | +33.42% | 1 | Feb 20, 2025 | |
| SYK Stryker | Maintains: Outperform | $378 → $405 | $390.40 | +3.74% | 11 | Oct 30, 2024 | |
| ALGN Align Technology | Maintains: Outperform | $325 → $276 | $187.74 | +47.01% | 18 | Oct 24, 2024 | |
| HSIC Henry Schein | Maintains: Outperform | $92 → $82 | $73.19 | +12.04% | 9 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $180 → $238 | $309.83 | -23.18% | 12 | Dec 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $70 | $32.26 | +116.99% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $61 | $14.07 | +333.55% | 4 | Jul 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $67 | $16.00 | +318.75% | 6 | Feb 18, 2022 |
The Cooper Companies
May 30, 2025
Maintains: Outperform
Price Target: $107 → $97
Current: $69.69
Upside: +39.19%
Envista Holdings
May 27, 2025
Upgrades: Outperform
Price Target: $21 → $23
Current: $19.65
Upside: +17.05%
Zimmer Biomet Holdings
May 6, 2025
Maintains: Outperform
Price Target: $130 → $115
Current: $91.74
Upside: +25.35%
DexCom
May 2, 2025
Maintains: Outperform
Price Target: $115 → $105
Current: $85.04
Upside: +23.47%
Tandem Diabetes Care
May 1, 2025
Maintains: Neutral
Price Target: $33 → $24
Current: $19.11
Upside: +25.59%
Alcon
Feb 27, 2025
Maintains: Outperform
Price Target: $104 → $108
Current: $87.17
Upside: +23.90%
Beta Bionics
Feb 20, 2025
Initiates: Neutral
Price Target: $20
Current: $14.99
Upside: +33.42%
Stryker
Oct 30, 2024
Maintains: Outperform
Price Target: $378 → $405
Current: $390.40
Upside: +3.74%
Align Technology
Oct 24, 2024
Maintains: Outperform
Price Target: $325 → $276
Current: $187.74
Upside: +47.01%
Henry Schein
Aug 7, 2024
Maintains: Outperform
Price Target: $92 → $82
Current: $73.19
Upside: +12.04%
Dec 21, 2023
Upgrades: Outperform
Price Target: $180 → $238
Current: $309.83
Upside: -23.18%
Aug 4, 2023
Maintains: Outperform
Price Target: $67 → $70
Current: $32.26
Upside: +116.99%
Jul 28, 2023
Maintains: Outperform
Price Target: $53 → $61
Current: $14.07
Upside: +333.55%
Feb 18, 2022
Maintains: Outperform
Price Target: $78 → $67
Current: $16.00
Upside: +318.75%